anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Taiwan has more chronic kidney disease (CKD) per capita than anywhere in the world, leading to the highest expense of National Health Insurance. By reviewing previous studies, uremic toxins contribute critically to the detrimental effects of CKD on atherosclerotic peripheral artery disease (PAD). When recognized early and managed appropriately, mortality and complications of the participants with CKD and established PAD can be minimized. It is critical to identify novel biomarkers and mediators, which can help identify those with potential poor outcomes and facilitate the discovery/development of novel therapeutics for the participants with CKD and PAD. The OMICs studies support the theory that gut microbiome is a major contributor to adverse cardiovascular outcomes and progression of CKD. However, successful integration of multi-omics approach remains sparse. There is no report on the impact of gut microbiota on the host circulating long non-coding RNAs (lncRNAs) expression signature, other CAD/PAD potential marker, and the potential link between gut microbiota, circulating lncRNA levels changes and CKD/PAD. Additionally, although numerous studies indicated that probiotics or activated charcoal have benefits for CKD patients, few studies evaluated the effect of coadministration of activated charcoal/probiotics on the participants with CKD/PAD. The mechanisms of therapeutic effect on CKD/PAD patients with coadministration of activated charcoal/probiotics involving the cross talk among host, microbiota and metabolites still remain unclear. Thus, in the present study, investigators aim to develop novel diagnostic/prognostic markers and a new treatment with activated bamboo charcoal (ABC)/probiotics for therapeutic opportunities to prevent cardiovascular complications, amputation and death in CKD patients with established PAD. To identify the diagnostic/prognostic markers, the multi-omics (microbolome and metabolome) and lncRNA will be analyzed. The therapeutic impact of activated bamboo charcoal (ABC)/probiotics with optimal formulation, on the renal/endothelial/vascular function, cardiovascular (CV) outcome and mortality in CKD patients with PAD will be also determined to evaluate its therapeutic opportunities. Additionally, the possible mechanisms including the molecular pathway and the roles of microbiota associated with expression profiles of lncRNA and metabolome linked to adverse CV/limb outcome will be investigation. Through combination of innovative molecular biological techniques with new approaches for clinical research, investigators will develop a novel therapy by updated knowledge of the mechanisms of disease and by improved pharmacological technology for the CKD patients with established PAD. Investigators expect to demonstrate the clinical efficacy of ABC ± probiotics to improve symptoms and outcomes of CKD patients with PAD, and offer a possibility to develop a precision medicine with novel diagnostic/prognostic markers and special ABC/probiotic formula, which will ultimately lead to the improved clinical care and outcomes in this population.
PURPOSE: A composition containing Plantago asiatica for preventing or treating neurodegenerative diseases is provided to reduce oxidative stress and enhance cell viability. CONSTITUTION: A pharmaceutical composition for preventing or treating neurodegenerative diseases contains Plantago asiatica extract. The disease is Alzheimver disease. The Plantago asiatica extract is isolated using ethanol extract. A pharmaceutical composition for preventing or treating neurodegeneratibe disesases contains 4-vinyl-2-methoxynol. A method for isolating the 4-vinyl-2-methoxynol comprises: a step of fractioning the extract with other organic solvent to obtain fraction; a step of passing the fraction through an open silica gel column to obtain brain-damaged suppression activity; and a step of performing HPLC.
PURPOSE: To obtain a makeup cosmetic excellent in pail foramen hiding effect by incorporating two kinds of silicone-based compounds in organopolysiloxane elastomer spherical powder having a specific particle diameter. CONSTITUTION: This makeup cosmetic comprises pref. 2-20wt.% of organopolysiloxane elastomer spherical powder with an average particle diameter of 1.0-15.0μm, pref. 5-75wt.% of a volatile silicone oil and pref. 0.1-20wt.% of a silicone resin [pref. a compound of the formula Rn SiO4-n/2 (R is a 1-6C hydrocarbon or phenyl; (n) is 1.0-1.8); the Rn SiO4-n/2 is an appropriate combination among R3 SiO1/2 units, R2 SiO units, RSiO3/2 units and SiO2 units so that the proportion for these units satisfy the above formula; the average molecular weight is about 1500-10000].
A large number of patients are affected by classical heart failure (HF) symptomatology with preserved ejection fraction (HFpEF) and multiorgan syndrome. Due to high morbidity and mortality rate, hospitalization and mortality remain serious socioeconomic problems, while the lack of effective pharmacological or device treatment means that HFpEF presents a major unmet medical need. Evidence from clinical and basic studies demonstrates that systemic inflammation, increased oxidative stress, and impaired mitochondrial function are the common pathological mechanisms in HFpEF. Tetrahydrobiopterin (BH4), beyond being an endogenous co-factor for catalyzing the conversion of some essential biomolecules, has the capacity to prevent systemic inflammation, enhance antioxidant resistance, and modulate mitochondrial energy production. Therefore, BH4 has emerged in the last decade as a promising agent to prevent or reverse the progression of disorders such as cardiovascular disease. In this review, we cover the clinical progress and limitations of using downstream targets of nitric oxide (NO) through NO donors, soluble guanylate cyclase activators, phosphodiesterase inhibitors, and sodium-glucose co-transporter 2 inhibitors in treating cardiovascular diseases, including HFpEF. We discuss the use of BH4 in association with HFpEF, providing new evidence for its potential use as a pharmacological option for treating HFpEF.
FIELD: veterinary immunology. SUBSTANCE: method involves blood sampling from animal, preparing 2.5% suspension of citrate blood and 2.5% suspension of washed off erythrocytes. Then citrate blood and washed off erythrocytes taken from the same animal are mixed separately with standard set of soluble bacterial and/or viral antigens. This mixing is carried out simultaneously. Result of reactions is recorded. The presence of this antigen in animal blood is diagnosed at positive erythrocyte reaction agglutination with any antigen and negative reaction of citrate blood with the same antigen. The presence of immune status with respect to this antigen in animal organism is diagnosed at positive erythrocyte agglutination or its absence with any antigen and positive reaction of citrate blood with the same antigen. Method can be used for express-diagnosis of diseases of viral and bacterial etiology. EFFECT: accelerated identification of viral and bacterial pathogens, enhanced effectiveness of immune status evaluation. 3 tbl
###  Effect on Estradiol

Mean serum concentrations of estradiol were evaluated in multiple daily dosing trials with 0.5, 1, 3, 5, and 10 mg of ARIMIDEX in postmenopausal women with advanced breast cancer. Clinically significant suppression of serum estradiol was seen with all doses. Doses of 1 mg and higher resulted in suppression of mean serum concentrations of estradiol to the lower limit of detection (3.7 pmol/L). The recommended daily dose, ARIMIDEX 1 mg, reduced estradiol by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing. Suppression of serum estradiol was maintained for up to 6 days after cessation of daily dosing with ARIMIDEX 1 mg.

The effect of ARIMIDEX in premenopausal women with early or advanced breast cancer has not been studied. Because aromatization of adrenal androgens is not a significant source of estradiol in premenopausal women, ARIMIDEX would not be expected to lower estradiol levels in premenopausal women.

###  Effect on Corticosteroids

In multiple daily dosing trials with 3, 5, and 10 mg, the selectivity of anastrozole was assessed by examining effects on corticosteroid synthesis. For all doses, anastrozole did not affect cortisol or aldosterone secretion at baseline or in response to ACTH. No glucocorticoid or mineralocorticoid replacement therapy is necessary with anastrozole.

###  Other Endocrine Effects

In multiple daily dosing trials with 5 and 10 mg, thyroid stimulating hormone (TSH) was measured; there was no increase in TSH during the administration of ARIMIDEX. ARIMIDEX does not possess direct progestogenic, androgenic, or estrogenic activity in animals, but does perturb the circulating levels of progesterone, androgens, and estrogens.
PROBLEM TO BE SOLVED: To provide a peroxisome proliferator-activated receptor (PPAR) activator, which is free from the problem of side effects, can be taken over a long term and has no characteristic taste.SOLUTION: A β-cryptoxanthin is employed as a PPAR activator. A large amount of the β-cryptoxanthin is contained in the pulp of citrus fruits (in particular, mandarin-type citrus fruits) such as satsuma mandarin oranges, for example, and has been consumed for many years. Thus, it is free from any problem in safety, and that has a low calorie content. Therefore, it can be taken over a long term. Also, because of being tasteless and odorless, the β-cryptoxanthin would not damage the taste unique to a food even when added to the food. Therefore, it can be added to foods and taken.
BACKGROUND: Tumor cells develop multiple mechanisms to facilitate their immune evasion. Identifying tumor-intrinsic factors that support immune evasion may provide new strategies for cancer immunotherapy. We aimed to explore the function and the mechanism of the tumor-intrinsic factor NPM1, a multifunctional nucleolar phosphoprotein, in cancer immune evasion and progression.
METHODS: The roles of NPM1 in tumor progression and tumor microenvironment (TME) reprogramming were examined by subcutaneous inoculation of Npm1-deficient tumor cells into syngeneic mice, and then explored by CyTOF, flow cytometry, immunohistochemistry staining, and RNA-seq. The in-vitro T-cell killing of OVA-presenting tumor cells by OT-1 transgenic T cells was observed. The interaction of NPM1 and IRF1 was verified by Co-IP. The regulation of NPM1 in IRF1 DNA binding to Nlrc5, Ciita promoter was determined by dual-luciferase reporter assay and ChIP-qPCR.
RESULTS: High levels of NPM1 expression predict low survival rates in various human tumors. Loss of NPM1 inhibited tumor progression and enhanced the survival of tumor-bearing mice. Npm1-deficient tumors showed increased CD8+ T cell infiltration and activation alongside the reduced presence of immunosuppressive cells. Npm1 deficiency increased MHC-I and MHC-II molecules and specific T-cell killing. Mechanistically, NPM1 associates with the transcription factor IRF1 and then sequesters IRF1 from binding to the Nlrc5 and Ciita promoters to suppress IRF1-mediated expression of MHC-I and MHC-II molecules in tumor cells.
CONCLUSIONS: Tumor-intrinsic NPM1 promotes tumor immune evasion via suppressing IRF1-mediated antigen presentation to impair tumor immunogenicity and reprogram the immunosuppressive TME. Our study identifies NPM1 as a potential target for improving cancer immunotherapy.
Semiconductor Laser Treatment Apparatus. Patients with primary lower extremity varicose veins were treated with endovenous laser treatment using Semiconductor Laser Treatment Apparatus. Ultrasound examination and questionnaire survey（AVVQ and VCSS) were performed at 1 week, 3 months, 6 months, 12 months after treatment,drug use and adverse events were recorded to assess complications and target lesion closure rate.
In the coronavirus pandemic, PCR testing is still the gold standard in the diagnosis of the disease. PCR with the right method can increase the sensitivity of the test. Adolescents' anxiety and anxiety levels may increase during invasive procedures such as PCR testing. In addition, in this process, factors such as the uncertainty created by the pandemic, disruption of routines, loss of school and peer social ties, and fear of getting sick bring along many mental disorders. The fact that the tests and treatments for the disease are new and that they are not informed about the procedures to be done cause the anxiety levels of the adolescents to increase. Nurses who treat adolescents with care and personal protective equipment may not be able to communicate verbally, sensorially, eye-to-eye with adolescents, and may have difficulty in conveying their voices and emotions. Likewise, by wearing a mask, it prevents nurses from observing their reactions to the hospital environment and procedures. Video education is one of the most effective ways for nurses to fulfill their educational roles during the epidemic when communication is limited. For this reason, it is very important to inform before the PCR sample collection process with a video prepared in accordance with the developmental stages of the adolescents. The aim of this study is to investigate the effect of the video that adolescents will watch before the procedure on their anxiety.
The invention relates to a helicobacter pylori specific antigen peptide, which comprises an amino acid sequence shown as SEQ ID No. 1. The antigen of the present invention can be used for preparing novel H .  pylori Vaccines and other uses H .  pylori Active or passive immunological therapy of treatment, of H .  pylori The prevention and treatment of infection is of great significance.
Different from other previous researches, the research discusses the action mechanism of the black tartary buckwheat stem and leaf extract on the treatment of type 2 diabetes by applying a biological method. The skeletal muscle cells are used as experimental objects to construct an experimental group for blocking a P13/Akt signal pathway, and then the stem and leaf extract of the black tartary buckwheat is given to analyze the expression of the related carbohydrate genes of the liver cells and discuss the cell mechanism of the stem and leaf extract of the black tartary buckwheat for treating the type 2 diabetes. At present, the research is not reported at home and abroad. Therefore, the black tartary buckwheat stem and leaf extract provides a novel treatment method. The method can save much expenses for purchasing db/db mice and double-gene knockout mice. The research detects the influence of the stem and leaf extract of the black tartary buckwheat on the insulin sensitivity of a mouse myoblast cell strain (C2C12) by measuring the protein expression level of an insulin receptor substrate P-IRS-1, and provides a theoretical basis for the treatment of type 2 diabetes.
Other Interactions: When the two drugs were taken concomitantly, decreased concentrations of atovaquone and increased concentrations of rifampin were observed.

Concurrent use of ketoconazole and rifampin has resulted in decreased serum concentrations of both drugs. Concurrent use of rifampin and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patient's clinical condition.

Concomitant antacid administration may reduce the absorption of rifampin. Daily doses of rifampin should be given at least 1 hour before the ingestion of antacids.

Probenecid and cotrimoxazole have been reported to increase the blood level of rifampin.

When rifampin is given concomitantly with either halothane or isoniazid, the potential of hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.

Plasma concentrations of sulfapyridine may be reduced following the concomitant administration of sulfasalazine and rifampin. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.
Breast cancer is the most prevalent malignant tumor in the world, and 30% of breast cancer patients will enter the advanced stage due to treatment failure. 80% of these patients have HER2-negative subtype breast cancer, which has not yet been found the similar target as HER2, with the median survival time of only 6-20 months. In the past, ovarian cancer patients faced the dilemma of poor survival due to the lack of precise targeted therapy. However, through a series of clinical studies, experts in the field of ovarian cancer have successfully expanded the indications of PARP inhibitor-based combination targeted therapy from the small population of BRCA mutation(20%) to the large population of HRD-positive (Homologous recombination deficiency) (50%), which has significantly prolonged the survival time of patients. Because causes other than BRCA mutations can also cause tumor cells to be "HRD" and thus sensitive to PARP inhibitors, so that HRD-positive patients are likely to benefit. The HRD-positive profile of nearly 50% of the patients could be a potential beneficiary of PARP inhibitor-based targeted therapy. The synergistic effect of PARP inhibitor and anti-angiogenic combination therapy has already been confirmed in preliminary cellular experiments and clinical studies related to ovarian cancer. Further cell-based experiments and preclinical studies have also confirmed the feasibility of the combination targeted therapy in the HRD-positive/HER2-negative subtype of breast cancer. Therefore, we intend to further validate the efficacy and safety of the PARP inhibitor fluazoparib in combination with the antiangiogenic abatinib in a Phase III, randomized, controlled clinical study, in order to provide HRD-positive/HER2-negative breast cancer patients with a better choice of precision targeted therapy.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition having high storage stability and excellent feeling in use by including a phospholipid prepared by converting a high oleic phospholipid. SOLUTION: This cosmetic comprises a lysophospholipid mixture in which >=30 mol.%, preferably >=70 mol.% of a fatty acid bonded to the mixture is a monoene fatty acid (preferably oleic acid) The content of a polyene fatty acid is preferably >=10 mol.% based on the whole fatty acid. The lysophospholipid is preferably obtained by hydrolyzing an acyl group at a specific site of a natural phospholipid with a phospholipase A1 or A2 . Preferably after the enzyme treatment, the lysophospholipid is purified with an organic solvent and used. A natural phospholipid mixture comprising >=30 mol.% of the monoene fatty acid and <=20 mol.% of the polyene fatty acid is preferable as the raw material natural phospholipid. In formulating a cosmetic with the lysophospholipid, the formulated amount of the lysophospholipid is preferably 0.1-5 wt.%.
Walkers continuously wear an actigraph watch to assess activity level. Daily sleep behavior is captured on an under-the-mattress sleep sensor. Participants walk 1-mile routes in triads, three times a week for 16 weeks while engaging in prompted conversational reminiscence recorded for a digital archive.
This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders associated with CD14 mediated cell activation, such as spesis.
Prolyl 4-hydroxylase subunit alpha 2 (P4HA2), a key enzyme modulating the post-transcription of proteins, was reported to be a causative gene in IA. Nevertheless, the exact function and mechanism of P4HA2 in the formation and rupture of IA is elusive. The current study first explored the expression of P4HA2 and its association with the clinicopathological demonstrations in patients with IA. In addition, an in vitro model of IA was established using H2O2 to stimulate vascular smooth muscle cells (VSMCs). The behaviors of treated VSMCs were evaluated using CCK-8, Wound healing, and Transwell assays. The expression of genes was detected by RT-qPCR and Western blot. Interaction between genes was confirmed using Luciferase Reporter assay and Co-immunoprecipitation (Co-IP) assay. Our results revealed that P4HA2 expression was upregulated in IA, especially ruptured IA; high P4HA2 expression correlates with unfavorable clinicopathological parameters. Through the in vitro experiments, it was discovered that P4HA2 knockdown rescued VSMCs from H2O2-induced viability impairment, enhancement in migration and apoptosis, switch from contractile phenotype, and augmentation of oxidative stress and inflammation. Mechanistically, P4HA2 was found to trigger the prolyl hydroxylation of YAP1 to negatively regulate the transcriptional activity of YAP1 in H2O2-challenged VSMCs. The effect of P4HA2 on H2O2-challenged VSMCs could be annulled by the mutation of YAP1 hydroxylation sites. In summary, P4HA2 served as a contributing factor during IA progression through its suppression on YAP1 activity by prolyl hydroxylation.
BACKGROUND: Emotional stress is a common precipitating cause of takotsubo cardiomyopathy (TC). Preexisting psychiatric disorder (PD) was linked to worsening outcomes in patients with TC1,2. However, there is limited data in literature to support this. This study aimed to determine the differences in outcomes in TC patients with and without PD.
METHODS: We identified all patients with a diagnosis of TC using the National Inpatient Sample (NIS) and the National Readmission Database (NRD) data from 2016 to 2018. The patients were separated into TC with PD group and TC without PD group. Multiple variable logistic regression was then performed.
RESULTS: Using NIS 2016-2018, we identified 23,220 patients with TC, and 43.11% had PD. The mean age was 66.73 ± 12.74 years, with 90.42% being female sex. The TC with PD group had a higher 30-readmission rate 1.25 (95% CI:1.06-1.47), Cardiogenic shock [aOR = 7.3 (95%CI 3.97-13.6), Mechanical ventilation [aOR = 4.2 (95%CI 2.4-7.5), Cardiac arrest [aOR = 2.6 (95%CI 1.1-6.3), than TC without PD group.
CONCLUSION: Psychiatric disorders were found in up to 43% of patients with TC. The concomitant PD in TC patients was not associated with increased mortality, AKI, but had higher rates of cardiogenic shock, use of mechanical ventilation and cardiac arrest. The TC group with PD was also associated with increased 30-day readmission, LOS and total charges compared to TC patients without PD.